Amanda M. Olson

2.8k total citations
22 papers, 1.1k citations indexed

About

Amanda M. Olson is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Amanda M. Olson has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Oncology and 4 papers in Cell Biology. Recurrent topics in Amanda M. Olson's work include PARP inhibition in cancer therapy (9 papers), DNA Repair Mechanisms (5 papers) and Cancer-related Molecular Pathways (4 papers). Amanda M. Olson is often cited by papers focused on PARP inhibition in cancer therapy (9 papers), DNA Repair Mechanisms (5 papers) and Cancer-related Molecular Pathways (4 papers). Amanda M. Olson collaborates with scholars based in United States and United Kingdom. Amanda M. Olson's co-authors include Eric F. Johnson, Cherrie K. Donawho, Yan Shi, Donald J. Osterling, Jennifer J. Bouska, David Maag, Sanjay C. Panchal, Enrico L. DiGiammarino, Todd A. Hopkins and Vincent L. Giranda and has published in prestigious journals such as Clinical Cancer Research, Journal of Medicinal Chemistry and European Journal of Cancer.

In The Last Decade

Amanda M. Olson

22 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amanda M. Olson United States	13	611	506	235	149	139	22	1.1k
Barbara Woynarowska Poland	19	244 0.4×	449 0.9×	134 0.6×	19 0.1×	25 0.2×	65	995
Naveed Iqbal United States	9	488 0.8×	403 0.8×	55 0.2×	22 0.1×	31 0.2×	28	1.1k
Patriciu Achimaș-Cădariu Romania	19	289 0.5×	371 0.7×	47 0.2×	3 0.0×	124 0.9×	96	1.2k
Yong Jia United States	16	224 0.4×	418 0.8×	157 0.7×	4 0.0×	107 0.8×	45	1.0k
Jingjing Song China	24	309 0.5×	660 1.3×	32 0.1×	22 0.1×	116 0.8×	81	1.7k
Amy Quinn United States	18	78 0.1×	994 2.0×	86 0.4×	9 0.1×	42 0.3×	32	1.7k
Fiza Rashid‐Doubell United Kingdom	18	69 0.1×	516 1.0×	90 0.4×	17 0.1×	36 0.3×	35	1.1k
Jane Li United States	16	76 0.1×	275 0.5×	69 0.3×	15 0.1×	21 0.2×	36	763
Linghui Zeng China	19	130 0.2×	466 0.9×	330 1.4×	106 0.7×	61 0.4×	83	1.4k
Manuela Klingler‐Hoffmann Australia	19	148 0.2×	651 1.3×	29 0.1×	27 0.2×	40 0.3×	52	1.2k

Countries citing papers authored by Amanda M. Olson

Since Specialization

Citations

This map shows the geographic impact of Amanda M. Olson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda M. Olson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda M. Olson more than expected).

Fields of papers citing papers by Amanda M. Olson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda M. Olson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda M. Olson. The network helps show where Amanda M. Olson may publish in the future.

Co-authorship network of co-authors of Amanda M. Olson

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda M. Olson. A scholar is included among the top collaborators of Amanda M. Olson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda M. Olson. Amanda M. Olson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maes, Estelle M., Kenneth J. Ruterbories, Stella Z. Doktor, et al.. (2023). Integrity and Efficiency: AbbVie’s Journey of Building an Integrated Nonregulated Bioanalytical Laboratory. Bioanalysis. 15(3). 161–176. 4 indexed citations

Tong, Yunsong, Alan S. Florjancic, Chunqiu Lai, et al.. (2021). Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors. ACS Medicinal Chemistry Letters. 12(7). 1108–1115. 2 indexed citations

Olson, Amanda M., et al.. (2020). A homologous series of internal standards for near universal application in the discovery LC-MS/MS bioanalytical laboratory. Journal of Pharmaceutical and Biomedical Analysis. 190. 113578–113578. 10 indexed citations

Hopkins, Todd A., Paul A. Ellis, Cherrie K. Donawho, et al.. (2018). PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow. Molecular Cancer Research. 17(2). 409–419. 173 indexed citations

Cassar, Steven, Amanda M. Olson, Xin Huang, et al.. (2017). Measuring drug absorption improves interpretation of behavioral responses in a larval zebrafish locomotor assay for predicting seizure liability. Journal of Pharmacological and Toxicological Methods. 88(Pt 1). 56–63. 24 indexed citations

Cassar, Steven, Amanda M. Olson, Wayne R. Buck, et al.. (2017). From the Cover: Inhibitors of Nicotinamide Phosphoribosyltransferase Cause Retinal Damage in Larval Zebrafish. Toxicological Sciences. 161(2). 300–309. 17 indexed citations

Hopkins, Todd A., Yan Shi, Luis E. Rodrı́guez, et al.. (2015). Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors. Molecular Cancer Research. 13(11). 1465–1477. 198 indexed citations

Tong, Yunsong, Maricel Torrent, Alan S. Florjancic, et al.. (2014). Pyrimidine-Based Tricyclic Molecules as Potent and Orally Efficacious Inhibitors of Wee1 Kinase. ACS Medicinal Chemistry Letters. 6(1). 58–62. 18 indexed citations

Curtin, Michael L., Robin R. Frey, H. Robin Heyman, et al.. (2012). Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. Bioorganic & Medicinal Chemistry Letters. 22(9). 3208–3212. 19 indexed citations

10.

Curtin, Michael L., H. Robin Heyman, Robin R. Frey, et al.. (2012). Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases. Bioorganic & Medicinal Chemistry Letters. 22(14). 4750–4755. 12 indexed citations

11.

Zhu, Gui‐Dong, Jianchun Gong, Viraj B. Gandhi, et al.. (2012). Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer. Bioorganic & Medicinal Chemistry. 20(15). 4635–4645. 24 indexed citations

12.

Curtin, Michael L., Robin R. Frey, Niru B. Soni, et al.. (2011). Abstract C202: Discovery and initial characterization of the clinical compound ABT-348, a potent inhibitor of the VEGF, PDGF, and Aurora kinase families.. Molecular Cancer Therapeutics. 10(11_Supplement). C202–C202. 1 indexed citations

13.

Miyashiro, Julie M., Keith W. Woods, Chang H. Park, et al.. (2009). Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorganic & Medicinal Chemistry Letters. 19(15). 4050–4054. 91 indexed citations

14.

Penning, Thomas D., Gui‐Dong Zhu, Viraj B. Gandhi, et al.. (2008). Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer. Journal of Medicinal Chemistry. 52(2). 514–523. 215 indexed citations

15.

Tong, Yunsong, Zhi‐Fu Tao, Jennifer J. Bouska, et al.. (2007). Cyanopyridyl containing 1,4-dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: Improving oral biovailability. Bioorganic & Medicinal Chemistry Letters. 17(20). 5665–5670. 5 indexed citations

16.

Dai, Yujia, Niru B. Soni, Lori J. Pease, et al.. (2007). Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(1). 386–390. 31 indexed citations

17.

Thomas, Sheela A., Tongmei Li, Keith W. Woods, et al.. (2006). Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase. Bioorganic & Medicinal Chemistry Letters. 16(14). 3740–3744. 11 indexed citations

18.

Plummer, E. Ruth, Mark R. Middleton, R. Wilson, et al.. (2005). Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide. Clinical Cancer Research. 11. 6 indexed citations

19.

Beck, Christina S., et al.. (2004). Enacting "Health Communication": The Field of Health Communication as Constructed Through Publication in Scholarly Journals. Health Communication. 16(4). 475–492. 31 indexed citations

20.

Murphy, James G., Jennifer J. Duchnick, Rudy E. Vuchinich, et al.. (2001). Relative efficacy of a brief motivational intervention for college student drinkers.. Psychology of Addictive Behaviors. 15(4). 373–379. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact